H-D-GLU(TRP-OH)-OH
H-D-GLU(TRP-OH)-OH Basic information
- Product Name:
- H-D-GLU(TRP-OH)-OH
- Synonyms:
-
- H-g-D-Glu-Trp-OH
- gamma-D-Glu-L-Trp
- Unii-637C487Y09
- GLU-TRP
- GAMMA-GLU-TRP
- H-D-GLU(TRP-OH)-OH
- H-GAMMA-GLU-TRP-OH
- H-GAMMA-D-GLU-TRP-OH
- CAS:
- 229305-39-9
- MF:
- C16H19N3O5
- MW:
- 333.34
- Mol File:
- 229305-39-9.mol
H-D-GLU(TRP-OH)-OH Chemical Properties
- Boiling point:
- 737.3±60.0 °C(Predicted)
- Density
- 1.428±0.06 g/cm3(Predicted)
- storage temp.
- −20°C
- solubility
- Soluble in DMSO
- pka
- 2.22±0.10(Predicted)
- form
- Solid
- color
- White to off-white
MSDS
- Language:English Provider:SigmaAldrich
H-D-GLU(TRP-OH)-OH Usage And Synthesis
Uses
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3].
Definition
ChEBI: Golotimod is a dipeptide.
in vivo
Golotimod (SCV-07) (oral gavage or subcutaneous injection, 100 μg/kg, 5 days) reduces experimental recurrent genital HSV-2 disease by oral administration, more importantly, oral SCV07 after fasting shows a greater reduction in incidence and severity than SCV-07 without fasting in female hartley guinea pigs[1].
Golotimod (SCV-07) (subcutaneous injection, once or twice a day from days 1 to 20, 100 μg/kg) can reduce the severity and duration of acute and split radiation-induced oral mucositis (OM) and short the duration of ulcerative OM in male LVG golden Syrian Hamsters[3].
| Animal Model: | Female Hartley guinea pigs (250-300 g) infected HSV-2[1] |
| Dosage: | 100 μg/kg |
| Administration: | Oral gavage or subcutaneous injection; 5 days |
| Result: | Reduced incidence of lesions from 55% (one week before treatment) to only 18% by oral administration, and showed no significant reduction in disease by subcutaneous injection of SCV-07. |
| Animal Model: | Male LVG golden Syrian Hamsters weighing approximately 80 g with radiation-induced mucositis[3] |
| Dosage: | 10, 100 μg/kg or 1 mg/kg |
| Administration: | Subcutaneous injection; once or twice a day from days 1 to 20 |
| Result: | Showed a peak mucositis of 3.0 on day 18 in the control group compared to only 2.2 in the test group, and the mucositis score in the SCV-07 treated hamsters was only 6.3% compared to 28.1% in the control group at dose of 100 μg/kg. Significantly decreased the severity and duration of oral mucositis (OM) at dose of 10 μg/kg, 100 μg/kg or 1 mg/kg. |
IC 50
STAT3
References
[1] Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2). Int J Antimicrob Agents. 2008 Sep;32(3):262-6. DOI:10.1016/j.ijantimicag.2008.04.010
[2] Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92. DOI:10.1016/j.oraloncology.2015.11.022
[3] Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis. 2010 Oct;16(7):655-60. DOI:10.1111/j.1601-0825.2010.01671.x
H-D-GLU(TRP-OH)-OHSupplier
- Tel
- sales@boylechem.com
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 028-62070218 18190869852
- sales@lavemc.com